June 2002
Volume 43, Issue 6
Free
Immunology and Microbiology  |   June 2002
Effect of Immunosuppression on Gene Expression in the HSV-1 Latently Infected Mouse Trigeminal Ganglion
Author Affiliations
  • Shiro Higaki
    From the Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana; the
  • Bryan M. Gebhardt
    From the Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana; the
    Department of Microbiology, the
    Neuroscience Center, and the
  • Walter J. Lukiw
    From the Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana; the
    Neuroscience Center, and the
  • Hilary W. Thompson
    From the Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana; the
    Neuroscience Center, and the
  • James M. Hill
    From the Department of Ophthalmology, LSU Eye Center, New Orleans, Louisiana; the
    Department of Microbiology, the
    Neuroscience Center, and the
    Department of Pharmacology, Louisiana State University Health Sciences Center at New Orleans, New Orleans, Louisiana.
Investigative Ophthalmology & Visual Science June 2002, Vol.43, 1862-1869. doi:
  • Views
  • PDF
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to authenticated users only.
      Sign In or Create an Account ×
    • Get Citation

      Shiro Higaki, Bryan M. Gebhardt, Walter J. Lukiw, Hilary W. Thompson, James M. Hill; Effect of Immunosuppression on Gene Expression in the HSV-1 Latently Infected Mouse Trigeminal Ganglion. Invest. Ophthalmol. Vis. Sci. 2002;43(6):1862-1869.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

purpose. To determine alterations in expression of genes in herpes simples virus (HSV)-1 latently infected mouse trigeminal ganglia (TGs), after treatment with cyclophosphamide and dexamethasone.

methods. Scarified corneas of female BALB/c mice were inoculated with HSV-1 strain McKrae. Four weeks after inoculation, cyclophosphamide and dexamethasone were intravenously injected to induce HSV-1 reactivation. Uninfected mice were also treated with the immunosuppressants. Four groups of animals were studied: uninfected, not treated; uninfected, drug treated; latently infected, not treated; and latently infected, drug treated. PolyA+ mRNA from the TGs of each group was reverse transcribed, labeled with 32P, incubated on a 1185-gene array membrane, and analyzed by phosphorimaging. As a comparison and to confirm microarray results, semiquantitative RT-PCR was also performed for selected genes.

results. The immunosuppressive drugs significantly increased expression of two genes (calpactin 1 light chain and guanine nucleotide-binding protein α–stimulating polypeptide [GNAS]) in the ganglia of uninfected mice compared with those in untreated uninfected mice. Ten genes were shown to be significantly increased in the latent TGs of mice treated with immunosuppressants compared with latently infected untreated mice. These genes were prostaglandin E2 receptor EP4 subtype (PTGER4), insulin promoter factor 1 (IPF1), glutathione S-transferase μ2, cyclin D2, peripherin, plasma glutathione peroxidase, methyl CpG-binding protein 2, retinal S-antigen, ErbB2 proto-oncogene, and GNAS. Eight genes were shown to be significantly decreased in the HSV-1 latent TGs treated with the drugs, compared with untreated latently infected mice. These genes were peripheral myelin protein 22, decorin, transcription factor AP-1, dystroglycan 1, myelin protein zero, mitogen-activated protein kinase 3, prothymosin beta 4, and brain lipid-binding protein. The results obtained by semiquantitative RT-PCR were similar to those obtained by microarray analysis.

conclusions. Those genes with expression altered by immunosuppressive drug treatment may play an important role in ocular HSV-1 recurrence. Changes in expression of genes in the prostaglandin pathway, a transcription factor, and an enzyme in the cell cycle are considered especially important in HSV-1 reactivation by immunosuppression and are reviewed.

Herpes simplex virus (HSV)-1 establishes a latent state in sensory neurons and may reactivate throughout the life of the host. 1 2 3 4 Herpes reactivation may involve altered expression of cellular genes, such as increased expression of certain transcriptional activators and/or reduced expression of repressor factors. The determination of the qualitative and quantitative changes in host and viral transcripts during the transition from latency to reactivation may facilitate the development of therapeutics for the prevention of viral reactivation. Some 30 cellular proteins have been suggested to be involved in HSV-1 latency and reactivation. 5 6 7 8 These include transcription factors, such as cAMP response element binding protein, 9 10 11 lumen, 12 13 OCT-1 and OCT-2, 14 15 16 17 and c-jun 18 ; signal transduction factors, such as protein kinase C 19 and fibroblast growth factor 20 ; tumor necrosis factor-α 21 ; interferons 22 23 ; nerve growth factor 24 ; and cyclooxygenase (COX)-2. 25 Reverse transcription–polymerase chain reaction (RT-PCR) and Northern blot and Western blot analyses have been used to assay for cellular responses during viral latency and reactivation, although to date only a few cell-derived proteins have been investigated in each study. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25  
Microarray analysis is a powerful tool that permits the study of many genes at one time. Stingley et al. 26 prepared the first microarrays containing the 80 HSV-1 transcripts expressed during acute and latent infection. Using an HSV mutant, they found that the viral α27 gene plays a major role in the reduction of cellular gene expression. Khodarev et al. 27 hybridized cDNAs derived from three separate human cell lines infected with wild-type HSV and a mutant virus to a DNA array containing probes for 588 human genes. They reported an accumulation of mRNAs that encode for transcription factors and stress response proteins in cells in which the transcription of most cellular RNAs has been reduced. Tsavachidou et al. 28 examined the gene expression changes that occur in cellular mRNA levels in uninfected mouse TGs after explantation, by using gene array analysis. Many genes, including B-cell lymphoma 3–encoded protein, were altered in expression in the model. These microarray investigations were either in vitro or ex vivo. 26 27 28 We have used microarray analysis to identify nine genes in the HSV-1 latently infected mouse TGs that exhibited increased expression 1 hour after hyperthermia. 25 In that in vivo study, we used a mouse stress array (Clontech, Palo Alto, CA) containing sequences for 149 genes. To our knowledge, this is the only in vivo study involving microarray analysis to assess the cellular gene response to HSV-1 latency during reactivation. 
In the present study, we assessed gene expression in uninfected mouse TGs and those latently infected with HSV-1 after treatment with cyclophosphamide and dexamethasone. Our goal was to determine the cellular factors that are altered during immunosuppression-induced HSV-1 reactivation. Immunosuppression may induce transcription of a unique set of cellular mRNAs expressed in latently infected TGs that differ from the mRNAs expressed in latently infected TGs not exposed to the drugs. 
We report that the transcription of a large number of genes was altered by treatment with immunosuppressive drugs. Using an array membrane containing the probes for 1185 known genes, including nine housekeeping genes, altered expression of at least 18 genes was noted in the ganglia of latently infected drug-treated mice. Possibly some of these genes with expression altered by treatment of latent disease with immunosuppressive drugs are key in the genetic mechanism of HSV-1 reactivation. 
Materials and Methods
Mouse Eye Model of Immunosuppression
Five- to 7-week-old female BALB/c mice (National Cancer Institute, Bethesda, MD) were housed in the Louisiana State University Health Sciences Center animal care facility and maintained on laboratory chow and water ad libitum. All animals were treated according to the ARVO Statement for the Use of Animals in Ophthalmic and Vision Research. Mice were anesthetized with ketamine hydrochloride (1 mg/kg, Vetamine; Phoenix Scientific Inc., St. Joseph, MO), and xylazine (0.5 mg/kg; Taylor Pharmaceuticals, Decatur, IL). The corneas were scarified and inoculated with 3 μL of a viral suspension containing 2.5 × 104 plaque-forming units of HSV-1 strain McKrae. To verify corneal infection, slit lamp examinations and ocular swabs were performed on days 3 and 4 after inoculation. 
Four weeks after inoculation, when the corneas healed, the mice were given an intravenous (IV) injection of 5 mg cyclophosphamide (Sigma, St. Louis, MO) in 0.2 mL of water, and 24 hours later an IV injection of 0.2 mg dexamethasone (Sigma) in 0.2 mL of water. 29 30 31 Uninfected mice were also given drugs on the same schedule. One hour after the dexamethasone injection, the mice were killed, and the TGs were removed. Four groups of animals were studied: uninfected, not treated; uninfected, drug treated; latently infected, not treated; and latently infected, drug treated. Twenty-two mice (44 TGs) were examined in each group. 
Isolation of PolyA+ mRNA and cDNA Array Hybridization
Total RNA was isolated from the TGs in extraction reagent (TRIzol; Gibco BRL, Rockville, MD) and DNase, as part of a commercial pure total RNA labeling protocol (Atlas; Clontech). The RNA was spectrophotometrically scanned, and all samples had an absorbance ratio (A260/A280) of 2.0 or more. No significant differences in the spectral purity, rate of degradation, and yield were noted among the groups. The polyA+ mRNA fraction was obtained using biotinylated oligo (dT) and streptavidin-coated paramagnetic beads. PolyA+ mRNA was reverse transcribed with Moloney murine leukemia virus (MMLV) reverse transcriptase in the presence of [32P]-dATP (10 μCi/μL, 3000 Ci/mmol; 35 μCi per reaction; Amersham, Piscataway, NJ). cDNAs were purified in a nucleospin column and hybridized onto cDNA array panels (Atlas Mouse 1.2 Array; Clontech) with hybridization solution (ExpressHyb; Clontech). cDNA array nylon membranes were washed and exposed 25 32 33 according to the manufacturer’s protocol (PT 3140-1; Clontech). The mouse array has 1185 genes; the complete list can be found at http://www.clontech.com/atlas/genelists/index.shtml. There was approximately 1 × 107 cpm associated with each cDNA that was hybridized to an array membrane. For each cDNA preparation, two determinations were conducted. 
Data Analysis
Signal intensity data were obtained from two independent cDNA array panels with four groups by phosphorimaging onto molecular imaging screens, by using a molecular imager (model GS250; Bio-Rad, Hercules, CA). The labeled cDNA was hybridized to the array membrane for 18 hours, followed by 48 hours of exposure to the storage screens. The data were analyzed using software for Atlas array analysis (AtlasImage 2.0; Clontech). The signal intensities on a control membrane (no drug treatment) and an experimental membrane (drug-treated) were normalized 34 by a global method, according to the software user’s manual. The intensity obtained was compared between two groups (no drug treatment versus drug treated). Signal analytical parameters (signal ratio, signal difference, and common cDNA filter background correction) were adjusted so that gene targets exhibiting the largest nonimmunosuppression-to-immunosuppression changes exceeding a factor of 1.4 or more were reported. In one published study, a postnormalization cutoff of a twofold increase or decrease in measured level was used to define differential expression, although there is no established theoretical basis for selecting this level as significant. 35 For statistical analysis, any values that were increased or decreased 1.4-fold or more in either comparative group were used. Next, analysis of variance (ANOVA) was performed to assess the statistical significance of the genes listed in Table 1 . Statistical evaluations of the magnitude and direction of change in gene expression levels were conducted by two-level factorial ANOVA and followed by two-tailed protected t-tests. The factors (main effects) in this ANOVA model were immunosuppressive drug treatment and viral latency (+ or −). The Tukey method was used to correct the significance criterion levels for the number of multiple comparisons made. 36  
Semiquantitative RT-PCR
cDNA was synthesized using reverse transcriptase (SuperScript II; Gibco BRL, Carlsbad, CA), according to the manufacturer’s recommendations. Reverse transcription was performed using 5 μg RNA and 0.5 μg oligo(dT) primer. Table 2 lists sequences of mouse-specific oligonucleotide primer pairs. The cDNA sample was amplified in a buffer containing 1.5 mM MgCl2 (Perkin-Elmer, Oceanport, NJ), 0.2 mM of each dNTP (New England BioLabs, Beverly, MA), 0.5% DNA polymerase (AmpliTaq; Perkin-Elmer), and 0.2 μM of each primer pair. The conditions for PCR were as follows: an initial 10-minute denaturing step at 94°C and exponential cycles of 30 seconds at 94°C, 30 seconds at 52°C, and 1 minute at 72°C. The PCR products were examined by 2% agarose gel electrophoresis with ethidium bromide staining. To determine the relative levels of gene expression, semiquantitative analysis was performed by the method reported in Nakayama et al. 37 and Yokoi et al. 38 The optical density of each band was measured, and the background intensity was subtracted from the band density by using image-analysis software (Eagle Sight 3; Stratagene, La Jolla, CA). For estimation of the initial amount of the template, the equation y = ax + b, where y is the logarithm of the PCR product’s intensity, a is the efficiency of amplification every cycle, x is the number of cycles, and b is the initial amount of the template, was fitted to the data in the linear portion of the graphs. 36 The ratio of the initial amount of each gene to GAPDH was compared for each sample. These experiments were repeated at least twice for each sample and primer pair. 
Results
Microarray
The results of the microarray phosphorimaging of uninfected and latently infected TGs are shown in Figures 1 and 2 : uninfected, nonimmunosuppression (Fig. 1A) ; uninfected, immunosuppression (Fig. 1B) ; HSV-1 latently infected, nonimmunosuppression (Fig. 2A) ; and HSV-1 latently infected, immunosuppression (Fig. 2B) . Signals were not seen in the negative control spots, indicating the one area of specificity of the hybridization. To determine the reproducibility of the results, a series of experiments was performed twice (eight hybridizations to eight microarray membranes). The results were remarkably similar, and the signal intensity readings for each gene were averaged from the two experiments. The lists of statistically significant (ANOVA, protected t-test, P < 0.05) genes with expression that increased or decreased greater than 1.4-fold are presented in Table 1 . Two genes in the TGs of uninfected, drug-treated mice exhibited increased expression. The TGs of latently infected, drug-treated mice showed increased expression of 10 genes and reduced expression of 8 genes. 
Semiquantitative RT-PCR
Five genes whose transcriptional level was altered by the drug treatment were analyzed by semiquantitative RT-PCR. The genes studied were inhibitor of DNA-binding protein 4 (ID4), PTGER4, cyclin D2, transcription factor activator protein (AP)-1, and myelin protein zero. Semiquantitative RT-PCR yielded results consistent with microarray results for each of the five genes studied (Figs. 3 4 ; Table 3 ). 
Discussion
Our ultimate goal is to prevent reactivation of HSV-1 and recurrent disease by inhibiting or stimulating host genes required for ocular recurrence of HSV-1. In this study, the transcriptional activity of 10 genes was significantly increased, and the transcriptional level of 8 genes was decreased in latently infected mice treated with cyclophosphamide and dexamethasone, compared with untreated latently infected mice. 
The involvement of cellular proteins in HSV latency and reactivation has been reviewed. 5 6 7 8 Some of the host cell proteins thought to be important in latency and reactivation have been noted in the introduction. 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 28 By microarray analysis, we 25 showed previously that nine genes including transcription factor II, DNAJ-like heat shock protein, stress-activated c-jun kinase 3 (JNK3), and COX-2 underwent transcriptional activation 1 hour after hyperthermia. 
The results of the present study and other published observations 5 6 7 8 18 19 25 28 39 40 indicate that PTGER4, cyclin D2, transcription factor AP-1, mitogen-activated protein kinase (MAPK), and IPF1 could have important roles in HSV-1 infection and reactivation. The expression of these genes is thought to be altered in response to immunosuppressive induction of uninfected or HSV latently infected neurons or viral replication after reactivation. To determine this, we must investigate when viral and cellular genes begin to change after induction of immunosuppression. Furthermore, it is difficult to determine in the current experiments whether induction of immunosuppression was caused primarily by the cyclophosphamide or primarily by the dexamethasone. It is possible that neither cyclophosphamide nor dexamethasone alone could reactivate latent HSV. 29 Stroop and Schaefer 29 reported that injection of dexamethasone or cyclophosphamide alone did not reactivate latent HSV-1 in rabbits; only 3% and 1% of eyes were positive for HSV-1 in rabbits receiving cyclophosphamide or dexamethasone, in contrast to the reactivation frequency of 85% observed when the drugs were administered together. They suggested that these two drugs act in a synergistic manner. If changes in gene expression are examined only after injection of cyclophosphamide or dexamethasone, fewer genes may be altered than were changed in the present study. Naray-Fejes-Toth et al. 41 reported that an initial effect of dexamethasone was to increase the expression of the glucocorticoid-induced kinase (SGK) gene. Time course analyses revealed that SGK mRNA levels are elevated as early as 30 minutes after exposure to the glucocorticoid, and the levels remain elevated for several hours. Using this observation, we selected the drug treatment protocol used in this study. 
We noted a significant increase in expression of the PTGER4 gene, which codes for a prostaglandin receptor. In this study, expression of the PTGER4 gene was increased 25-fold in latently infected TGs after drug treatment and only 1.2-fold in drug-treated uninfected TGs. Although microarray analysis showed that expression of PTGER4 was increased 25-fold in drug-treated, latently infected TGs, semiquantitative RT-PCR indicated only a 3.05-fold upregulation of gene expression. According to previous reports, 42 43 44 45 46 the changes in gene expression obtained from an array system are usually similar to, but are not always identical with, those obtained from semiquantitative RT-PCR. 42 43 Glucocorticoids attenuate expression of COX-2, and deregulated expression of COX-2 leads to an overproduction of prostaglandins. 47 Also, perhaps the upregulation of this gene is a host response to reactivation of HSV-1, similar to that seen in acute cytomegalovirus infection. 48  
The expression of the cyclin D2 gene was increased to similar levels after drug treatment of uninfected and latently infected mice. Cyclin D consists of three subtypes of cyclins (D1, D2, and D3). Cyclin D2 is implicated in cell cycle regulation, differentiation, and oncogenic transformation. Cellular cyclin-dependent kinases (CDKs) are required for HSV replication. 40 41 Inhibitors of CDK-1, -2, and -5 inhibit viral replication. 40 41 Because members of the cyclin D family bind to and activate CDK-4 and CDK-6, inhibitors of these genes may prevent HSV-1 reactivation. 
In this study, the genes for transcription factor AP-1 and MAPK-3 exhibited reduced transcription after immunosuppression. AP-1 can regulate many aspects of cell physiology in response to environmental changes. 49 Fos and Jun constitute the prototypic components of the AP-1 complex. MAPKs have been implicated in many physiological processes and phosphorylate Jun proteins. 50 Acute HSV-1 infection, bacterial infection, and emotional stress activate p38/c-Jun N-terminal MAPK pathways, resulting in the elevation of activity of AP-1 and expression of corticotropin-releasing hormone, thus acting on the adrenal cortex to cause the release of glucocorticoids. 47 51 Glucocorticoids are circulated to a variety of tissues where they bind to receptors, leading to inhibition of AP-1–mediated gene induction. 47 51 Our results and those of Millhouse and Wigdahl 7 suggest that AP-1 plays an important role in directing both the establishment and reactivation of latent HSV infection. 
Of the genes with transcriptional activity reduced by drug treatment, peripheral myelin protein 22 (PMP22) underwent the largest decrease (0.44-fold in latently infected TGs, 0.42-fold in uninfected TGs). PMP22 plays a crucial role in normal physiological and pathologic processes in the peripheral nervous system. It functions in cell growth, differentiation, and apoptosis. 52 Further investigation is necessary to understand the significance of regulation of PMP22 by immunosuppression in the TG. 
IPF1 is selectively expressed in the β cells and transactivates the insulin promoter. It is required in early development of the pancreas, and it may act either at the level of determination or the early differentiation of the pancreas. 53 No relationship between IPF1 and herpes viruses has been reported to date, but further studies are needed. 
Recently, Tsavachidou et al. 28 reported the gene expression changes in uninfected mouse TGs after explantation using a gene array (Gene Discovery Array Mouse I; Gene Systems, Menlo Park, CA). In their studies, increased expression of genes including prostaglandin endoperoxidase, cyclin-dependent kinase, cyclin F, transcription factor S-II, and glutathione S-transferase was noted. In contrast, myelin gene expression decreased. Although the investigators studied uninfected TGs and ex vivo events, some of the same genes, such as PTGER4, glutathione S-transferase μ2, cyclin D2, PMP22, and transcription factor AP-1, were altered in their study as in our present study of HSV-1–latent TGs induced in vivo. 
HSV-1 can be induced to reactivate by UV irradiation, 1 2 3 trauma, 2 heat stress, 54 cold stress, 55 and adrenergic iontophoresis. 56 57 58 To better understand the interactions between the host and the virus, we plan in future experiments to investigate changes in gene expression after the use of these other inducers. 
In summary, 18 genes were significantly altered after injection of cyclophosphamide and dexamethasone in mice latently infected with HSV-1. One or more of these genes could hold the key to the prevention of recurrence of ocular herpes. If substances that regulate these genes can be shown to block viral reactivation, such agents could form a new class of antiviral medication. 
 
Table 1.
 
Changes in Gene Transcription in Mouse TGs after Immunosuppression with Dexamethasone and Cyclophosphamide
Table 1.
 
Changes in Gene Transcription in Mouse TGs after Immunosuppression with Dexamethasone and Cyclophosphamide
Gene GenBank Accession Number Intensity Ratio P
Untreated Immunosuppression
Uninfected Trigeminal Ganglia
 Genes showing increased transcription*
  Calpactin 1 light chain M16465 14157.5 ± 8437.9 20944.5 ± 11096.6 1.52 ± 0.12 0.0023
  GNAS Y00703 8317.0 ± 5762.9 16081.5 ± 6491.9 2.19 ± 0.74 0.0006
HSV-Latent Trigeminal Ganglia
 Genes showing increased transcription, †
  PTGER4 D13458 98.5 ± 12.0 2476.5 ± 122.3 25.26 ± 1.84 <0.0001
  IPF1 X74342 460.0 ± 7.1 2979.0 ± 314.0 6.49 ± 0.56 <0.0001
  Glutathione S-transferase μ2 J04696 1259.5 ± 0.7 2012.5 ± 112.4 1.60 ± 0.09 <0.0001
  Cyclin D2 M83749 1915.5 ± 94.0 2676.0 ± 186.7 1.40 ± 0.17 <0.0001
  Peripherin X15475 686.0 ± 128.7 1134.5 ± 157.7 1.71 ± 0.55 0.0167
  Plasma glutathione peroxidase U13705 713.5 ± 6.4 1137.5 ± 40.0 1.60 ± 0.11 0.0233
  Methyl CpG-binding protein 2 AF072251 1281.0 ± 206.5 1904.5 ± 53.0 1.51 ± 0.29 0.0011
  Retinal S-antigen M24086 917.5 ± 161.9 1304.5 ± 273.7 1.42 ± 0.05 0.0379
  ErbB2 proto-oncogene L47239 1582.0 ± 176.8 2181.0 ± 123.4 1.36 ± 0.06, † 0.0016
  GNAS Y00703 4195.0 ± 130.1 4873.0 ± 479.4 1.15 ± 0.09, † 0.0004
 Genes showing decreased expression, ‡
  Peripheral myelin protein 22 M32240 1669.5 ± 78.5 747.0 ± 328.1 0.44 ± 0.18 <0.0001
  Decorin X53929 2575.0 ± 219.2 1435.0 ± 91.9 0.56 ± 0.01 <0.0001
  Transcription factor AP-1 J04115 2599.0 ± 220.6 1588.0 ± 476.6 0.62 ± 0.24 <0.0001
  Dystroglycan 1 U43512 1167.5 ± 0.7 610.5 ± 280.7 0.52 ± 0.24 0.0033
  Myelin protein zero M62860 1938.5 ± 27.6 1340.5 ± 98.3 0.69 ± 0.04 0.0017
  Mitogen-activated protein kinase M61177 1318.0 ± 82.0 907.5 ± 456.1 0.70 ± 0.39 0.02793
  Prothymosin beta 4 X16053 3834.5 ± 129.4 3313.0 ± 383.3 0.86 ± 0.14, ‡ 0.0057
  Brain lipid-binding protein S69799 3948.0 ± 418.6 3518.0 ± 2.8 0.88 ± 0.88, ‡ 0.0215
Table 2.
 
Mouse-Specific Primer Sequences and Sizes of RT-PCR Products
Table 2.
 
Mouse-Specific Primer Sequences and Sizes of RT-PCR Products
Gene Orientation 5′-3′ Sequence Sizes of Amplified Fragments (bp)
GAPDH Sense 5′-TGAAGGTCGGTGTGAACGGATTTGGC-3′ 983
Antisense 5′-CATGTAGGCCATGAGGTCCACCAC-3′
PTGER4 Sense 5′-TTCCGCTCGTGGTGCGAGTGTTC-3′ 423
Antisense 5′-GAGGTGGTGTCTGCTTGGGTCAG-3′
Cyclin D2 Sense 5′-AGAGACCATCCCGCTGACTGC-3′ 434
Antisense 5′-GCAGGCTGTTCAGCAGCAGAG-3′
Inhibitor of DNA-binding protein 4 Sense 5′-CACGTTCACGAGCATTCACCGTAC-3′ 195
Antisense 5′-CTTGTCACAATGTAGCCTCTAAGGTTG-3′
Transcription factor AP-1 Sense 5′-ATGCCCTCAACGCCTCGTTCCTCC-3′ 288
Antisense 5′-CTGCTCGTCGGTCACGTTCTTGGG-3′
Myelin protein zero Sense 5′-ACTATGCCAAGGGACAACCTTACATC-3′ 196
Antisense 5′-ACATAGAGCGTGACCTGAGAGGTC-3′
Figure 1.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Uninfected mice, not treated; (B) uninfected mice, drug treated. cDNA array panels are divided into seven theme-targeted sectors, including (a) basic transcription factors, (b) cell-cycle regulation, (c) oncogenes, (d) chemokine-cytokine signaling, (e) signal transduction, (f) cytoskeleton proteins and DNA damage repair proteins, and (g) housekeeping genes. Arrows: cDNA spots that show significant increases in expression.
Figure 1.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Uninfected mice, not treated; (B) uninfected mice, drug treated. cDNA array panels are divided into seven theme-targeted sectors, including (a) basic transcription factors, (b) cell-cycle regulation, (c) oncogenes, (d) chemokine-cytokine signaling, (e) signal transduction, (f) cytoskeleton proteins and DNA damage repair proteins, and (g) housekeeping genes. Arrows: cDNA spots that show significant increases in expression.
Figure 2.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Latent mice, not treated; (B) latent mice, drug-treated. The seven theme-targeted sectors are the same as in Figure 1 . Arrows: cDNA spots that show significant increases in expression. Arrowheads: spots that show significantly decreased cDNA expression.
Figure 2.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Latent mice, not treated; (B) latent mice, drug-treated. The seven theme-targeted sectors are the same as in Figure 1 . Arrows: cDNA spots that show significant increases in expression. Arrowheads: spots that show significantly decreased cDNA expression.
Figure 3.
 
Representative results of semiquantitative RT-PCR. The graphs show the cycle–intensity curves of each reaction. The equation y = ax + b was fitted in the linear portion. The graphs shown are the GAPDH and ID4 transcripts in uninfected (A) and latently infected (B) mice. IMS: immunosuppression.
Figure 3.
 
Representative results of semiquantitative RT-PCR. The graphs show the cycle–intensity curves of each reaction. The equation y = ax + b was fitted in the linear portion. The graphs shown are the GAPDH and ID4 transcripts in uninfected (A) and latently infected (B) mice. IMS: immunosuppression.
Figure 4.
 
Representative results of semiquantitative RT-PCR. IMS: immunosuppression.
Figure 4.
 
Representative results of semiquantitative RT-PCR. IMS: immunosuppression.
Table 3.
 
Density Ratios of Untreated and Drug-Treated HSV Latently Infected TGs by Semiquantitative RT-PCR and Microarray
Table 3.
 
Density Ratios of Untreated and Drug-Treated HSV Latently Infected TGs by Semiquantitative RT-PCR and Microarray
Uninfected Latent
RT-PCR Microarray RT-PCR Microarray
ID4 0.74 ± 0.13 0.84 ± 0.15 0.38 ± 0.07 0.57 ± 0.06
PTGER4 1.07 ± 0.02 1.25 ± 0.24 3.05 ± 0.49 25.26 ± 1.84
Cyclin D2 1.33 ± 0.39 1.46 ± 0.19 1.51 ± 0.21 1.40 ± 0.17
Transcription factor AP-1 0.64 ± 0.11 0.66 ± 0.46 0.65 ± 0.05 0.62 ± 0.24
Myelin protein zero 0.61 ± 0.10 0.53 ± 0.18 0.61 ± 0.14 0.69 ± 0.04
The authors thank Maxine S. Evans and Will E. Close (LSU Eye Center) for technical support, Michael K. Smolek (LSU Eye Center) for computational assistance, and David C. Bloom (Department of Molecular Genetics and Microbiology, University of Florida, Gainesville, Florida) and Craig S. Miller (Department of Oral Health Practice, University of Kentucky College of Dentistry, Louisville, Kentucky) for reading the manuscript. 
Stevens JG. Human herpesvirus: a consideration of the latent state. Microbiol Rev. 1989;53:318–332. [PubMed]
Hill JM, Wen R, Halford WP. Pathogenesis and molecular biology of ocular HSV in the rabbit. Brown MS Maclean AR eds. Methods in Molecular Medicine. 1998;291–315. Humana Press Totowa, NJ.
Cohrs RJ, Gilden DH. Human herpesvirus latency. Brain Pathol. 2001;11:465–474. [CrossRef] [PubMed]
Whitley RJ, Roizman B. Herpes simplex virus infections. Lancet. 2001;357:1513–1518. [CrossRef] [PubMed]
Boehmer PE. Herpes simplex virus DNA replication. Annu Rev Biochem. 1997;66:347–384. [CrossRef] [PubMed]
Miller CS, Danaher RJ, Jacob RJ. Molecular aspects of herpes simplex virus 1 latency, reactivation, and recurrence. Crit Rev Oral Biol Med. 1998;9:541–562. [CrossRef] [PubMed]
Millhouse S, Wigdahl B. Molecular circuitry regulating herpes simplex virus type 1 latency in neurons. J Neurovirol. 2000;6:6–24. [CrossRef] [PubMed]
Preston CM. Repression of viral transcription during herpes simplex virus latency. J Gen Virol. 2000;81:1–19. [PubMed]
Ackland-Berglund CE, Davido DJ, Leib DD. The roles of the cAMP-response element and TATA box in expression of the herpes simplex virus type 1 latency-associated transcripts. Virology. 1995;210:141–151. [CrossRef] [PubMed]
Huang QS, Deshmane SL, Fraser NW. An in vitro ligation and transfection system for inserting DNA sequences into the latency-associated transcripts (LATs) gene of herpes simplex virus type 1. Gene Ther. 1994;1:300–306. [PubMed]
Kenny JJ, Krebs FC, Hartle HT, et al. Identification of a second ATF/CREB-like element in the herpes simplex virus type 1 (HSV-1) latency-associated transcript (LAT) promoter. Virology. 1994;200:220–235. [CrossRef] [PubMed]
Lu R, Yang P, Padmakumar S, Misra V. The herpesvirus transactivator VP16 mimics a human basic domain leucine zipper protein, Luman, in its interaction with HCF. J Virol. 1998;72:6291–6297. [PubMed]
Lu R, Misra V. Potential role for Luman, the cellular homologue of herpes simplex virus VP16 (α gene trans-inducing factor), in herpesvirus latency. J Virol. 2000;74:934–943. [CrossRef] [PubMed]
Hagmann M, Georgiev O, Schaffner W, Douville P. Transcription factors interacting with herpes simplex virus α gene promoters in sensory neurons. Nucleic Acids Res. 1995;23:4978–4985. [CrossRef] [PubMed]
Lillycrop KA, Dent CL, Wheatley SC, et al. The octamer-binding protein Oct-2 repress HSV immediate-early genes in cell lines derived from latently infectable sensory neurons. Neuron. 1991;7:381–390. [CrossRef] [PubMed]
Lillycrop KA, Liu YZ, Theil T, Moroy T, Latchman DS. Activation of the herpes simplex virus immediate-early gene promoters by neuronally expressed POU family transcription factors. Biochem J. 1995;307:581–584. [PubMed]
Stern S, Tanaka M, Herr W. The Oct-1 homeodomain directs formation of a multiprotein-DNA complex with the HSV transactivator VP16. Nature. 1989;341:624–630. [CrossRef] [PubMed]
Valyi-Nagy T, Deshmane S, Dillner A, Fraser NW. Induction of cellular transcription factors in trigeminal ganglia of mice by corneal scarification, herpes simplex virus type 1 infection, and explantation of trigeminal ganglia. J Virol. 1991;65:4142–4152. [PubMed]
Smith RL, Pizer LI, Johnson EM, Jr, Wilcox CL. Activation of second-messenger pathways reactivates latent herpes simplex virus in neuronal cultures. Virology. 1992;188:311–318. [CrossRef] [PubMed]
Jordan R, Pepe J, Schaffer PA. Characterization of a nerve growth factor-inducible cellular activity that enhances herpes simplex virus type 1 gene expression and replication of an ICP0 null mutant in cells of neural lineage. J Virol. 1998;72:5373–5382. [PubMed]
Cunningham ET, Jr, Stalder A, Sanna PP, et al. Localization of tumor necrosis factor receptor messenger RNA in normal and herpes simplex virus infected mouse eyes. Invest Ophthalmol Vis Sci. 1997;38:9–15. [PubMed]
Cantin EM, Hinton DR, Chen J, Openshaw H. Gamma interferon expression during acute and latent nervous system infection by herpes simplex virus type 1. J Virol. 1995;69:4898–4905. [PubMed]
Tal-Singer R, Podrzucki W, Lanser TM, et al. Use of differential display reverse transcription-PCR to reveal cellular changes during stimuli that result in herpes simplex virus type 1 reactivation from latency: upregulation of immediate-early cellular response genes TIS7, interferon, and interferon regulatory factor-1. J Virol. 1998;72:1252–1261. [PubMed]
Hill JM, Garza HH, Helmy SD, et al. Nerve growth factor antibody stimulates reactivation of ocular herpes simplex virus type 1 in latently infected rabbits. J Neurovirol. 1997;3:206–211. [CrossRef] [PubMed]
Hill JM, Lukiw WJ, Gebhardt BM, et al. Gene expression analyzed by microarrays in HSV-1 latent mouse trigeminal ganglion following heat stress. Virus Genes. 2001;23:273–280. [CrossRef] [PubMed]
Stingley SW, Ramirez JJ, Aguilar SA, et al. Global analysis of herpes simplex virus type 1 transcription using an oligonucleotide-based DNA microarray. J Virol. 2000;74:9916–9927. [CrossRef] [PubMed]
Khodarev NN, Advani SJ, Gupta N, Roizman B, Weichselbaum RR. Accumulation of specific RNAs encoding transcriptional factors and stress response proteins against a background of severe depletion of cellular RNAs in cells infected with herpes simplex virus 1. Proc Natl Acad Sci USA. 1999;96:12062–12067. [CrossRef] [PubMed]
Tsavachidou D, Podrzucki W, Seykora J, Berger SL. Gene array analysis reveals changes in peripheral nervous system gene expression following stimuli that result in reactivation of latent herpes simplex virus type 1: induction of transcription factor bcl-3. J Virol. 2001;75:9909–9917. [CrossRef] [PubMed]
Stroop WG, Schaefer DC. Severity of experimentally reactivated herpetic eye disease is related to the neurovirulence of the latent virus. Invest Ophthalmol Vis Sci. 1987;28:229–237. [PubMed]
Cook SD, Paveloff MJ, Doucet JJ, Cottingham AJ, Sedarati F, Hill JM. Ocular herpes simplex virus reactivation in mice latently infected with latency-associated transcript mutants. Invest Ophthalmol Vis Sci. 1991;32:1558–1561. [PubMed]
Haruta Y, Rootman DS, Hill JM. Recurrent HSV-1 corneal lesions in rabbits induced by cyclophosphamide and dexamethasone. Invest Ophthalmol Vis Sci. 1989;30:371–376. [PubMed]
Lukiw WJ, Rogaev EI, Bazan NG. Synaptic and cytoskeletal RNA message levels in sporadic Alzheimer neocortex. Alzheimers Res. 1996;2:221–228.
Lukiw WJ, Carver LA, LeBlanc HJ, Bazan NG. Analysis of 1184 gene transcript levels in Alzheimer CA1 hippocampus: synaptic signaling and transcription factor deficits and upregulation of pro-inflammatory pathways. Alzheimer Rep. 2000;3:161–167.
Quackenbush J. The power of public access: the human genome project and the scientific process. Nat Genet. 2001;29:4–6. [CrossRef] [PubMed]
Quackenbush J. Computational analysis of microarray data. Nat Rev Genet. 2001;2:418–427. [CrossRef] [PubMed]
Sheskin DJ. Handbook of Parametric and Nonparametric Statistical Procedures. 2000;982. Chapman & Hall/CRC Boca Raton, FL:.
Nakayama H, Yokoi H, Fujita J. Quantification of mRNA by non-radioactive RT-PCR and CCD imaging system. Nucleic Acids Res. 1992;20:4939. [CrossRef] [PubMed]
Yokoi H, Natsuyama S, Iwai M, et al. Non-radioisotopic quantitative RT-PCR to detect changes in mRNA levels during early mouse embryo development. Biochem Biophys Res Commun. 1993;195:769–775. [CrossRef] [PubMed]
Schang LM, Rosenberg A, Schaffer PA. Roscovitine, a specific inhibitor of cellular cyclin-dependent kinases, inhibits herpes simplex virus DNA synthesis in the presence of viral early proteins. J Virol. 2000;74:2107–2120. [CrossRef] [PubMed]
Schang LM, Rosenberg A, Schaffer PA. Transcription of herpes simplex virus immediate-early and early genes is inhibited by roscovitine, an inhibitor specific for cellular cyclin-dependent kinases. J Virol. 1999;73:2161–2172. [PubMed]
Naray-Fejes-Toth A, Fejes-Toth G, Volk KA, Stokes JB. SGK is a primary glucocorticoid-induced gene in the human. J Steroid Biochem Mol Biol. 2000;75:51–56. [CrossRef] [PubMed]
Honda S, Farboud B, Hjelmeland LM, Handa JT. Induction of an aging mRNA retinal pigment epithelial cell phenotype by matrix-containing advanced glycation end products in vitro. Invest Ophthalmol Vis Sci. 2001;42:2419–2425. [PubMed]
Hamalainen H, Zhou H, Chou W, Hashizume H, Heller R, Lahesmaa R. Distinct gene expression profiles of human type 1 and type 2 T helper cells. Genome Biol. 2001;2:22.1–22.11.
Kihara C, Tsunoda T, Tanaka T, et al. Prediction of sensitivity of esophageal tumors to adjuvant chemotherapy by cDNA microarray analysis of gene-expression profiles. Cancer Res. 2001;61:6474–6479. [PubMed]
Konu O, Kane JK, Barrett T, et al. Region-specific transcriptional response to chronic nicotine in rat brain. Brain Res. 2001;909:194–203. [CrossRef] [PubMed]
Hayashida-Hibino S, Watanabe H, Nishida K, et al. The effect of TGF-beta1 on differential gene expression profiles in human corneal epithelium studied by cDNA expression array. Invest Ophthalmol Vis Sci. 2001;42:1691–1697. [PubMed]
Karin M, Chang L. AP-1-glucocorticoid receptor crosstalk taken to a higher level. J Endocrinol. 2001;169:447–451. [CrossRef] [PubMed]
Zhu H, Cong JP, Mamtora G, Gingeras T, Shenk T. Cellular gene expression altered by human cytomegalovirus: global monitoring with oligonucleotide arrays. Proc Natl Acad Sci USA. 1998;95:14470–14475. [CrossRef] [PubMed]
Wagner EF. AP-1 Introductory remarks. Oncogene. 2001;20:2334–2335. [CrossRef] [PubMed]
Rincon M, Flavell RA, Davis RJ. Signal transduction by MAP kinases in T lymphocytes. Oncogene. 2001;20:2490–2497. [CrossRef] [PubMed]
Zachos G, Clements B, Conner J. Herpes simplex virus type 1 infection stimulates p38/c-Jun N-terminal mitogen-activated protein kinase pathways and activates transcription factor AP-1. J Biol Chem. 1999;274:5097–5103. [CrossRef] [PubMed]
Jetten AM, Suter U. The peripheral myelin protein 22 and epithelial membrane protein family. Prog Nucleic Acids Res. 2000;64:97–129.
Jonsson J, Carlsson L, Edlund T, Eduland H. Insulin-promoter-factor 1 is required for pancreas development in mice. Nature. 1994;371:606–609. [CrossRef] [PubMed]
Sawtell NM, Thompson RL. Rapid in vivo reactivation of herpes simplex virus in latently infected murine ganglionic neurons after transient hyperthermia. J Virol. 1992;66:2150–2156. [PubMed]
Varnell ED, Kaufman HE, Hill JM, Thompson HW. Cold stress-induced recurrences of herpetic keratitis in the squirrel monkey. Invest Ophthalmol Vis Sci. 1995;36:1181–1183. [PubMed]
Kwon BS, Gangarosa LP, Park NH, et al. Effect of iontophoretic and topical application of antiviral agents in treatment of experimental HSV-1 keratitis in rabbits. Invest Ophthalmol Vis Sci. 1979;18:984–988. [PubMed]
Hill JM, Kwon BS, Shimomura Y, Colbom GL, Yaghmai F, Gangarosa LP. Herpes simplex virus recovery in neural tissues after ocular HSV shedding induced by epinephrine iontophoresis to the rabbit cornea. Invest Ophthalmol Vis Sci. 1983;24:243–247. [PubMed]
Shimomura Y, Gangarosa LP, Sr, Kataoka M, Hill JM. HSV-1 shedding by iontophoresis of 6-hydroxydopamine followed by topical epinephrine. Invest Ophthalmol Vis Sci. 1983;24:1588–1594. [PubMed]
Figure 1.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Uninfected mice, not treated; (B) uninfected mice, drug treated. cDNA array panels are divided into seven theme-targeted sectors, including (a) basic transcription factors, (b) cell-cycle regulation, (c) oncogenes, (d) chemokine-cytokine signaling, (e) signal transduction, (f) cytoskeleton proteins and DNA damage repair proteins, and (g) housekeeping genes. Arrows: cDNA spots that show significant increases in expression.
Figure 1.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Uninfected mice, not treated; (B) uninfected mice, drug treated. cDNA array panels are divided into seven theme-targeted sectors, including (a) basic transcription factors, (b) cell-cycle regulation, (c) oncogenes, (d) chemokine-cytokine signaling, (e) signal transduction, (f) cytoskeleton proteins and DNA damage repair proteins, and (g) housekeeping genes. Arrows: cDNA spots that show significant increases in expression.
Figure 2.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Latent mice, not treated; (B) latent mice, drug-treated. The seven theme-targeted sectors are the same as in Figure 1 . Arrows: cDNA spots that show significant increases in expression. Arrowheads: spots that show significantly decreased cDNA expression.
Figure 2.
 
Each phosphorimage is a representative example of microarray analysis of polyA+ mRNA from the TGs of mice. (A) Latent mice, not treated; (B) latent mice, drug-treated. The seven theme-targeted sectors are the same as in Figure 1 . Arrows: cDNA spots that show significant increases in expression. Arrowheads: spots that show significantly decreased cDNA expression.
Figure 3.
 
Representative results of semiquantitative RT-PCR. The graphs show the cycle–intensity curves of each reaction. The equation y = ax + b was fitted in the linear portion. The graphs shown are the GAPDH and ID4 transcripts in uninfected (A) and latently infected (B) mice. IMS: immunosuppression.
Figure 3.
 
Representative results of semiquantitative RT-PCR. The graphs show the cycle–intensity curves of each reaction. The equation y = ax + b was fitted in the linear portion. The graphs shown are the GAPDH and ID4 transcripts in uninfected (A) and latently infected (B) mice. IMS: immunosuppression.
Figure 4.
 
Representative results of semiquantitative RT-PCR. IMS: immunosuppression.
Figure 4.
 
Representative results of semiquantitative RT-PCR. IMS: immunosuppression.
Table 1.
 
Changes in Gene Transcription in Mouse TGs after Immunosuppression with Dexamethasone and Cyclophosphamide
Table 1.
 
Changes in Gene Transcription in Mouse TGs after Immunosuppression with Dexamethasone and Cyclophosphamide
Gene GenBank Accession Number Intensity Ratio P
Untreated Immunosuppression
Uninfected Trigeminal Ganglia
 Genes showing increased transcription*
  Calpactin 1 light chain M16465 14157.5 ± 8437.9 20944.5 ± 11096.6 1.52 ± 0.12 0.0023
  GNAS Y00703 8317.0 ± 5762.9 16081.5 ± 6491.9 2.19 ± 0.74 0.0006
HSV-Latent Trigeminal Ganglia
 Genes showing increased transcription, †
  PTGER4 D13458 98.5 ± 12.0 2476.5 ± 122.3 25.26 ± 1.84 <0.0001
  IPF1 X74342 460.0 ± 7.1 2979.0 ± 314.0 6.49 ± 0.56 <0.0001
  Glutathione S-transferase μ2 J04696 1259.5 ± 0.7 2012.5 ± 112.4 1.60 ± 0.09 <0.0001
  Cyclin D2 M83749 1915.5 ± 94.0 2676.0 ± 186.7 1.40 ± 0.17 <0.0001
  Peripherin X15475 686.0 ± 128.7 1134.5 ± 157.7 1.71 ± 0.55 0.0167
  Plasma glutathione peroxidase U13705 713.5 ± 6.4 1137.5 ± 40.0 1.60 ± 0.11 0.0233
  Methyl CpG-binding protein 2 AF072251 1281.0 ± 206.5 1904.5 ± 53.0 1.51 ± 0.29 0.0011
  Retinal S-antigen M24086 917.5 ± 161.9 1304.5 ± 273.7 1.42 ± 0.05 0.0379
  ErbB2 proto-oncogene L47239 1582.0 ± 176.8 2181.0 ± 123.4 1.36 ± 0.06, † 0.0016
  GNAS Y00703 4195.0 ± 130.1 4873.0 ± 479.4 1.15 ± 0.09, † 0.0004
 Genes showing decreased expression, ‡
  Peripheral myelin protein 22 M32240 1669.5 ± 78.5 747.0 ± 328.1 0.44 ± 0.18 <0.0001
  Decorin X53929 2575.0 ± 219.2 1435.0 ± 91.9 0.56 ± 0.01 <0.0001
  Transcription factor AP-1 J04115 2599.0 ± 220.6 1588.0 ± 476.6 0.62 ± 0.24 <0.0001
  Dystroglycan 1 U43512 1167.5 ± 0.7 610.5 ± 280.7 0.52 ± 0.24 0.0033
  Myelin protein zero M62860 1938.5 ± 27.6 1340.5 ± 98.3 0.69 ± 0.04 0.0017
  Mitogen-activated protein kinase M61177 1318.0 ± 82.0 907.5 ± 456.1 0.70 ± 0.39 0.02793
  Prothymosin beta 4 X16053 3834.5 ± 129.4 3313.0 ± 383.3 0.86 ± 0.14, ‡ 0.0057
  Brain lipid-binding protein S69799 3948.0 ± 418.6 3518.0 ± 2.8 0.88 ± 0.88, ‡ 0.0215
Table 2.
 
Mouse-Specific Primer Sequences and Sizes of RT-PCR Products
Table 2.
 
Mouse-Specific Primer Sequences and Sizes of RT-PCR Products
Gene Orientation 5′-3′ Sequence Sizes of Amplified Fragments (bp)
GAPDH Sense 5′-TGAAGGTCGGTGTGAACGGATTTGGC-3′ 983
Antisense 5′-CATGTAGGCCATGAGGTCCACCAC-3′
PTGER4 Sense 5′-TTCCGCTCGTGGTGCGAGTGTTC-3′ 423
Antisense 5′-GAGGTGGTGTCTGCTTGGGTCAG-3′
Cyclin D2 Sense 5′-AGAGACCATCCCGCTGACTGC-3′ 434
Antisense 5′-GCAGGCTGTTCAGCAGCAGAG-3′
Inhibitor of DNA-binding protein 4 Sense 5′-CACGTTCACGAGCATTCACCGTAC-3′ 195
Antisense 5′-CTTGTCACAATGTAGCCTCTAAGGTTG-3′
Transcription factor AP-1 Sense 5′-ATGCCCTCAACGCCTCGTTCCTCC-3′ 288
Antisense 5′-CTGCTCGTCGGTCACGTTCTTGGG-3′
Myelin protein zero Sense 5′-ACTATGCCAAGGGACAACCTTACATC-3′ 196
Antisense 5′-ACATAGAGCGTGACCTGAGAGGTC-3′
Table 3.
 
Density Ratios of Untreated and Drug-Treated HSV Latently Infected TGs by Semiquantitative RT-PCR and Microarray
Table 3.
 
Density Ratios of Untreated and Drug-Treated HSV Latently Infected TGs by Semiquantitative RT-PCR and Microarray
Uninfected Latent
RT-PCR Microarray RT-PCR Microarray
ID4 0.74 ± 0.13 0.84 ± 0.15 0.38 ± 0.07 0.57 ± 0.06
PTGER4 1.07 ± 0.02 1.25 ± 0.24 3.05 ± 0.49 25.26 ± 1.84
Cyclin D2 1.33 ± 0.39 1.46 ± 0.19 1.51 ± 0.21 1.40 ± 0.17
Transcription factor AP-1 0.64 ± 0.11 0.66 ± 0.46 0.65 ± 0.05 0.62 ± 0.24
Myelin protein zero 0.61 ± 0.10 0.53 ± 0.18 0.61 ± 0.14 0.69 ± 0.04
×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×